A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of almotriptan malate
(AXERT®) in treating acute migraine headaches in adolescents. Amotriptan malate (AXERT®) is
approved for use in the treatment of acute migraine headache with or without aura in adults.
In this study, adolescents will be given a single dose of study medication to treat one
migraine headache.